1,637 reports of this reaction
2.1% of all FLUDARABINE PHOSPHATE reports
#8 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #8 most commonly reported adverse reaction for FLUDARABINE PHOSPHATE, manufactured by Fresenius Kabi USA, LLC. There are 1,637 FDA adverse event reports linking FLUDARABINE PHOSPHATE to CYTOMEGALOVIRUS INFECTION. This represents approximately 2.1% of all 79,367 adverse event reports for this drug.
Patients taking FLUDARABINE PHOSPHATE who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for FLUDARABINE PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for FLUDARABINE PHOSPHATE:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 1,637 FDA reports for FLUDARABINE PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 2.1% of all adverse event reports for FLUDARABINE PHOSPHATE, making it a notable side effect.
If you experience cytomegalovirus infection while taking FLUDARABINE PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.